Compare Applied Materials, Inc. (AMAT) vs ResMed Inc. (RMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Applied Materials, Inc. vs ResMed Inc. — how do they compare? Applied Materials, Inc. trades at $582 (market cap $478.36B), while ResMed Inc. trades at $198.7 (market cap $29.57B). The key difference: Applied Materials, Inc. is far larger — about 16.2× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.18%). Which is the better fit depends on your goals.
| AMAT | RMD | |
|---|---|---|
Market Cap | $478.36B | $29.57B |
Sector | Technology | Health |
52-Week High | $723.00 | $293.73 |
52-Week Low | $156.25 | $182.82 |
Enterprise Value | $477.39B | $28.76B |
Dividend Yield | 0.35% | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Applied Materials (AMAT) trades at $602.50, up 2.35% today, with strong earnings beats in recent quarters and a consensus analyst price target of $644.33. The stock shows a bullish moving average signal but neutral oscillators, with key resistance at $617 and support at $573. Revenue grew to $28.37B in 2025, with a net income margin of 24.66%, though valuation ratios like P/E of 56.68 are elevated. Recent news highlights CEO Gary Dickerson's optimism on AI-driven semiconductor demand, positioning AMAT for multi-year growth.
The outlook for AMAT is positive, driven by AI infrastructure expansion and consistent earnings outperformance. Risks include high valuation multiples and semiconductor cycle volatility. With 76.9% of analysts rating it a buy and institutional sentiment bullish, the stock offers growth potential but requires monitoring of execution and market conditions.
ResMed (RMD) trades at $203.87, down 2.2% today, but maintains strong fundamentals with consistent earnings beats and robust profitability. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show a bullish trend with support at $202, while fundamentals reveal impressive 27.4% net margins and steady revenue growth from $5.15B in 2025 to projected $5.5B in 2026.
RMD presents a compelling investment case with 28% upside to analyst consensus target of $254.57, supported by strong cash flow generation and strategic business optimization. Key risks include competitive pressures in the sleep apnea market and potential market share challenges from new pharmaceutical treatments. The balanced analyst coverage (15 Buy, 15 Hold, 5 Sell) suggests cautious optimism amid the company's solid execution and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applied Materials, Inc.
Applied Materials is the world's largest supplier of semiconductor manufacturing equipment, providing materials engineering solutions to help make nearly every chip in the world. The firm's systems are used in nearly every major process step with the exception of lithography. Key tools include those for chemical and physical vapor deposition, etching, chemical mechanical polishing, wafer- and reticle-inspection, critical dimension measurement, and defect-inspection scanning electron microscopes.
Read more on AMAT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
